Link Immunotherapeutics

Dual Bispecifics

Link Immunotherapeutics is developing immunotherapies with greater selectivity for tumors over normal tissue. To enable better patient responses to cancer therapies, Link is using an approach that balances affinity and avidity to generate novel immunotherapies. This approach involves selecting validated cancer targets and novel target combinations to build on existing knowledge to create better molecules. Ultimately, Link is building a team of strong individuals with unique skills and expertise to develop best-in-class and first-in-class antibody therapies.